

AMENDMENTS TO THE CLAIMS

PURSUANT TO REVISED 37 CFR § 1.21

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1-48. (Cancelled)

49. (Previously Presented) A method of treatment, comprising:

- a) providing
 - i) a mammal having a plurality of symptoms of sepsis, wherein said symptoms comprise arterial hypotension and at least one selected from the group consisting of metabolic acidosis, fever, decreased systemic vascular resistance, tachypnea, and organ failure,
 - ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and
- b) administering said preparation to said mammal wherein said symptoms are reduced.

50. (Previously Presented) The method of Claim 49, wherein said antibodies are polyclonal.

51. (Previously Presented) A therapeutic composition for use with a mammal having a plurality of symptoms of sepsis, wherein said symptoms comprise arterial hypotension and at least one selected from the group consisting of metabolic acidosis, fever, decreased systemic vascular resistance, tachypnea, and organ failure, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.

52. (Previously Presented) A method of treatment, comprising:

- a) providing:
 - i) a mammal having sepsis,
 - ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and
- b) administering said preparation to said mammal wherein said sepsis is reduced.

53. (Previously Presented) The method of Claim 52, wherein said antibodies are polyclonal.

54. (Previously Presented) A therapeutic composition for use with a mammal having sepsis, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.

55. (Previously Presented) A method of treatment, comprising:

- a) providing:
 - i) a mammal having septic shock,
 - ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and
- b) administering said preparation to said mammal wherein said septic shock is reduced.

56. (Currently Amended) The method of Claim 55 49, wherein said antibodies are polyclonal.

57. (Previously Presented) A therapeutic composition for use with a mammal having septic shock, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.